Stages II-III Breast Cancer


Breast Cancer Awareness Month: Ask Questions, Get Connected (October 1, 2016)

What does breast cancer awareness month mean to you? We’d like to hear from you—join us on facebook, twitter, or CancerConnect and join the discussion. On October 10th  at 6pm EDT, we will have... Continue Reading

Neratinib Improves Cancer-Free Survival in Early Breast Cancer (July 27, 2016)

The targeted agent neratinib (PB272), which is still in clinical trials, demonstrated an improvement in cancer-free survival when used after Herceptin® (trastuzumab) in early-stage, HER2-positive breast... Continue Reading

Some Premenopausal Women Benefit from Exemestane Compared to Tamoxifen (April 28, 2016)

Among premenopausal women with hormone-positive, early breast cancer who are considered to have a high risk of a cancer recurrence, the use of Aromasin® (exemestane) versus tamoxifen improves cancer-free... Continue Reading

Men’s Views of the Women They Love Post-Mastectomy (April 11, 2016)

By John Leifer Despite five decades of effort by feminists, our society continues to bombard women with the message that their femininity and sexual attractiveness are directly tied to their bust-line.... Continue Reading

Dose-Dense Chemotherapy for Premenopausal Breast Cancer Improves Survival (March 28, 2016)

Premenopausal women who have been diagnosed with breast cancer have improved survival if their chemotherapy doses are delivered every two weeks, compared to every three weeks. These results were recently... Continue Reading

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated... Continue Reading

Conjugate Drug Extends Survival in Patients with Advanced HER2-Positive Breast Cancer (January 6, 2016)

Patients with metastatic, HER2-positive breast cancer received a combination antibody/chemotherapy drug in a phase 3 clinical trial survived longer, on average, than patients receiving other treatments.... Continue Reading

A Vegan or Vegetarian Diet May Help Improve Treatment of Triple-Negative Breast Cancer (September 16, 2015)

Early research suggests that a vegan or vegetarian diet low in the amino acid methionine may help improve treatment of triple-negative breast cancers. These findings were reported in the journal Clinical... Continue Reading

Biomarker May Help Improve Treatment of Triple-Negative Breast Cancer (September 8, 2015)

Researchers have found a biomarker that appears active in the growth and spread of triple-negative breast cancer. Known as interleukin-13 receptor alpha 2 (IL13Ralpha2), the biomarker may help doctors... Continue Reading

Women with Early Breast Cancer Have Fewer Side Effects with Shorter Courses of Radiation (September 1, 2015)

Women with early breast cancer have fewer side effects when they’re treated with shorter courses of radiation at higher doses than with conventional radiation to the whole breast. These findings were... Continue Reading

Role of Tumor Size and Estrogen-Receptor Status in Decline in Breast Cancer Deaths (August 4, 2015)

In light of a general decline in breast cancer death since the late 1980s, research has now turned to how type and stage of disease affect survival among different women. These findings, which considered... Continue Reading

Dose-Dense Chemotherapy with Ellence®, Cytoxan®, and Taxol® May Improve Survival in Node-Positive Breast Cancer (April 30, 2015)

Patients with early-stage node-positive breast cancer who receive dose-dense adjuvant chemotherapy with Ellence® (epirubicin), Cytoxan® (cyclophosphamide), and Taxol® (paclitaxel) may have improved... Continue Reading

Herceptin Superior to Tykerb for Treatment of HER2-positive Breast Cancer (March 24, 2015)

CancerConnect News: In patients with human epidermal growth factor receptor (HER2)–positive advanced breast cancer, the combination of Herceptin® (trastuzumab) plus a taxane resulted in delayed time... Continue Reading

Palbociclib/Letrozole Improves Outcomes of Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer (February 27, 2015)

The results of the phase II PALOMA-1/TRIO-18 trial were recently reported in The Lancet Oncology and suggest that the addition of Ibrance® (palbociclib) to Femara® (letrozole) delayed the time to cancer... Continue Reading

Afinitor® plus Herceptin® and Paclitaxel Effective in Advanced Hormone Receptor-Negative HER2-Positive Breast Cancer (February 5, 2015)

The combination of Afinitor® (everolimus) plus Herceptin® (trastuzumab) paclitaxel appears effective for patients with advanced HER2-positive breast cancer that is hormone receptor (HR)-negative. These... Continue Reading

Breast Cancer Research: Have We Made Progress? (January 27, 2015)

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included... Continue Reading

Study Confirms Role of Ovarian Suppression and Aromasin for Younger Women With Hormone-sensitive Breast Cancer (December 19, 2014)

CancerConnect News: Ovarian suppression combined with the anti-estrogen drug Aromasin® (exemestane) appears to greatly reduce the risk of breast cancer recurrence in younger women according to the results... Continue Reading

Breast Cancer Patients Are Now Living Longer without Relapse (December 18, 2014)

CancerConnect News: Survival without relapse for patients with early-stage breast cancer has improved significantly over the past 30 years, particularly among women with HER2-positive disease. These findings... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS